Stockscreener 앱 받기
186.99
0.47%
0.88
시간 외 거래:
187.01
0.02
+0.01%
Abbvie Inc 주식(ABBV)의 최신 뉴스
Immunology Market Deep Research Report Signals Rapid GrowthAbbVie Inc., Johnson & Johnson - openPR.com
Meta, JPMorgan, Gap And A Health Care Stock On CNBC's 'Final Trades' - Benzinga
AbbVie Inc. (ABBV) and Chicago Cubs Launch “Striking Out Cancer” Campaign - Insider Monkey
AbbVie announces multi-year partnership with the Chicago Cubs - TipRanks
AbbVie (ABBV) Gains As Market Dips: What You Should Know - Yahoo Finance
Final Trades: JPMorgan, Meta, Abbvie and Gap - CNBC
AbbVie Partners with Chicago Cubs on "Striking Out Cancer" | ABB - GuruFocus
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV)June 3, 2025 Deadline to Join – Contact Levi & Korsinsky - TradingView
AbbVie’s ADC win shows how pharma can break through in solid tumors - Pharma Voice
AbbVie (ABBV) Stock Dips in Morning Trade: What Key Numbers Reveal - Daily Chhattisgarh News
Analyst recommendations: AbbVie, Emerson Electric, Marriott International, Zscaler, and Monster Beverage… - marketscreener.com
AbbVie (ABBV) Partners with Chicago Cubs for Cancer Awareness In - GuruFocus
AbbVie (ABBV) Partners with Chicago Cubs for Cancer Awareness Initiative | ABBV Stock News - GuruFocus
AbbVie Partners with Chicago Cubs on "Striking Out Cancer" - PR Newswire
How Is AbbVie's Stock Performance Compared To Other Pharmaceuticals Stocks? - Barchart.com
Berenberg Adjusts Price Target on AbbVie to $170 From $195, Maintains Hold Rating - marketscreener.com
The Zacks Analyst Blog Highlights Berkshire Hathaway, AbbVie, Intuitive Surgical, Hamilton Beach Brands and AXIL Brands - Yahoo Finance
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. LawsuitABBV - marketscreener.com
Top Research Reports for Berkshire Hathaway, AbbVie & Intuitive Surgical - MSN
Contact The Gross Law Firm by June 3, 2025 Deadline to Join Class Action Against Cerevel Therapeutics Holdings, Inc.(ABBV) - TradingView
AbbVie Stock Down Around 13% in 3 Months: Time to Buy the Dip? - Yahoo Finance
AbbVie: Fairly Valued, But Lacking A Spark - Seeking Alpha
Cancer Therapeutics Market Is Booming So Rapidly 2025-2032 - openPR.com
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for InvestorsContact The Gross Law Firm - marketscreener.com
AbbVie Inc. (ABBV)’s Pipeline Advances with Temab-A and ABBV-706, Shares Flat - Yahoo Finance
Sarah Cannon Research Institute Announces Strategic Alliance with AbbVie to Advance Novel Cancer Therapies - marketscreener.com
CERE DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Cerevel Therapeutics Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - GlobeNewswire Inc.
AbbVie (NYSE:ABBV) Showcases Promising Phase 1 ADC Results For Advanced Cancers - Yahoo Finance
Bearish Sentiment and Increased Put Activity for AbbVie (ABBV) | - GuruFocus
AbbVie put volume heavy and directionally bearish - TipRanks
Sarah Cannon Research Institute Announces Strategic Alliance With AbbVie to Advance Novel Cancer Therapies - BioSpace
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? - sharewise
Targeted Drug Delivery Research Business Analysis Report 2024-2030 with Focus on 30+ Key Players Such as AbbVie, Amgen, AstraZeneca, Becton Dickinson and Co, & Bristol-Myers Squibb - GlobeNewswire
AbbVie’s Allergan cuts over 200 staff after botched marketing campaign - PharmaLive
AbbVie’s Allergan Cuts Over 200 Staff After Botched Marketing Campaign - BioSpace
AbbVie Inc. (ABBV) Scores Major Legal Victory as Illinois Court Shuts Down $63 Billion Allergan Shareholder Lawsuit - MSN
AbbVie To Present Cancer Trial Data At Upcoming ASCO Event - Benzinga
AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio - Investing News Network
AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio | ABBV Stock News - GuruFocus
Tissue Engineering Market Generated Opportunities, Future - openPR.com
Prurigo Nodularis Market - GlobeNewswire Inc.
AbbVie’s SWOT analysis: biopharma giant faces pipeline challenges amid stock growth - Investing.com
Precision immunology Market Growth in Future Scope 2025-2032 | - openPR.com
Immunomodulatory Drugs Market in 2025 Detailed Study Analysis | - openPR.com
Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie - insights.citeline.com
CERE DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - GlobeNewswire Inc.
AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer - MSN
Key Drivers Behind AbbVie’s (ABBV) Performance - Insider Monkey
Levi & Korsinsky Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineABBV - marketscreener.com
AbbVie (NYSE:ABBV) Faces Legal Scrutiny Over Merger With Cerevel - Yahoo Finance
0.12%
0.77%
자본화:
|
볼륨(24시간):